Moussy, Alain
AB Science (France)
5 papers on CoChat
Most cited papers
- Verified
ALS clinical trials review: 20 years of failure. Are we any closer to registering a new treatment?
Petrov, D., Mansfield, C., Moussy, A., & Hermine, O. (2017) · Frontiers in Aging Neuroscience
Amyotrophic Lateral Sclerosis ResearchAlzheimer's disease research and treatments
Cited by 451
- Verified
Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT
Dubreuil, P., Letard, S., Ciufolini, M., Gros, L., Humbert, M., Castéran, N., Borge, L., Hajem, B., Lermet, A., Sippl, W., et al. (2009) · PLoS ONE
Mast cells and histamineGastrointestinal Tumor Research and Treatment
Cited by 421
- Verified
Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations
Bodemer, C., Hermine, O., Palmérini, F., Yang, Y., Grandpeix-Guyodo, C., Leventhal, P. S., Hadj-Rabia, S., Nasca, L., Georgin-Lavialle, S., Cohen-Akenine, A., et al. (2010) · Journal of Investigative Dermatology
Mast cells and histamineGastrointestinal Tumor Research and Treatment
Cited by 397
- Verified · note
Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis: A Randomized, Phase 3, Clinical Trial
Vermersch, P., Brieva-Ruiz, L., Fox, R. J., Paul, F., Ramio-Torrenta, L., Schwab, M., Moussy, A., Mansfield, C., Hermine, O., Maciejowski, M., et al. (2022) · Neurology Neuroimmunology & Neuroinflammation
Multiple Sclerosis Research StudiesPolyomavirus and related diseases
Cited by 74
- Verified
Correction: Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial
Dubois, B., López‑Arrieta, J., Lipschitz, S., Doskas, T., Spiru, L., Moroz, S., Venger, O., Vermersch, P., Moussy, A., Mansfield, C. D., et al. (2023) · Alzheimer's Research & Therapy
Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research
Cited by 10
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free